||PENN Medicine and the Abramson
Cancer Center of the University of Pennsylvania announce the
establishment of the Center for Research on Early
Detection and Cure of Ovarian Cancer.
||The Center will be directed by internationally
renowned gynecologic oncologist and research scientist, George
Coukos, MD, PhD.
||Penn’s Center for Research on Early Detection and Cure
of Ovarian Cancer features three research programs: Early Detection
and Prevention Program; Advanced Therapeutics Program; and the
Cancer Biology and Pathogenesis Program.
The Abramson Cancer Center of the University
the University of Pennsylvania Health System
and Penn’s Department
of Obstetrics and Gynecology
today the establishment of the Center for Research on Early
Detection and Cure of Ovarian Cancer.
Center, to be directed by internationally renowned gynecologic
oncologist and research scientist, George
Coukos, MD, PhD,
focus on developing better detection methods, new treatment therapies,
and improving the quality of life for women with ovarian
“There was a tremendous need for this Center and to advance
the fight against ovarian cancer,” said Coukos, Center Director
and Director of Gynecologic Oncology Research at Penn. “The
need for early detection is crucial to win this fight. If caught
in Stage I, the five-year survival rate of ovarian cancer is over
90 percent. If caught in Stage III, the survival rate drops to
less than 30 percent.”
A. Driscoll, MD, Chair of Penn’s
Department of Obstetrics and Gynecology, “This new Center
will provide an infrastructure for ovarian cancer research and
treatment and will serve as a catalyst to unite existing talent
at Penn, recruit new investigators, and promote interdisciplinary
collaboration in the field of ovarian cancer.”
Penn’s Center for Research on Early Detection and Cure of
Ovarian Cancer features three research programs:
Cancer Early Detection and Prevention Program
Lack of early detection or prevention strategies is
presently a major cause of poor outcomes in ovarian cancer patients.
A screening test for ovarian cancer could save many lives. The
research laboratory activities of the Early Detection and Prevention
Program focus upon improving the outcomes of ovarian cancer by
facilitating the development of new blood tests, new imaging
tools, and other innovative techniques, as well as prevention
Cancer Advanced Therapeutics Program
This Program will develop novel therapies and will conduct
clinical trials to test emerging concepts from the laboratory.
The Facilities for the new clinical program will be located
Center for Advanced Medicine, to open in 2008.
Cancer Biology and Pathogenesis Program
All striving to better understand the pathogenesis
and biology of ovarian cancer, several multi-disciplinary laboratories
will focus on various aspects of ovarian cancer genomics, genetics,
immunology and biology. The discoveries within the laboratories
are crucial for the Early Detection and Prevention Program as
well as the Advanced Therapeutics Program.
PENN Medicine is a $2.9 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt
of NIH research funds; and ranked #3 in the nation in U.S. News
& World Report's most recent ranking of top research-oriented
medical schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its superior
education and training of the next generation of physician-scientists
and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals,
all of which have received numerous national patient-care honors [Hospital
of the University of Pennsylvania; Pennsylvania Hospital, the nation's
first hospital; and Penn Presbyterian Medical Center]; a faculty practice
plan; a primary-care provider network; two multispecialty satellite
facilities; and home care and hospice.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.